Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial - Concepedia

Concepedia

Publication | Open Access

Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial

DOI Full Paper Access

35

Citations

20

References

2021

Year

Binghe Xu, Qingyuan Zhang, Tao Sun, Wei Li, Yuee Teng, Xichun Hu, Igor Bondarenko, Hryhoriy Adamchuk, Liangming Zhang, Dmytro Trukhin,

References

	Year	Citations

Page 1